Previous Close | 4.6700 |
Open | 4.6100 |
Bid | 4.6100 x 1100 |
Ask | 5.0400 x 1000 |
Day's Range | 4.6100 - 5.0599 |
52 Week Range | 1.4300 - 10.9700 |
Volume | 65,711 |
Avg. Volume | 389,353 |
Market Cap | 76.571M |
Beta (5Y Monthly) | 0.70 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1930 |
Earnings Date | May 15, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
The substantially improved pharmacological profile of GP532 opens new opportunities for broader therapeutic applications of this class of pharmaceuticalsBUFFALO, NY / ACCESSWIRE / April 14, 2021 / Genome Protection, Inc. (GPI), a joint venture between Cleveland BioLabs, Inc.
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: